Healthcare provider profile · identity verified

Daniel Wesley Williams, APRN

Nurse Practitioner · BAXTER SPRINGS, KS · NPI 1447762984

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Alprazolam	Alprazolam	254	45
Atorvastatin Calcium	Atorvastatin Calcium	242	77
Lisinopril	Lisinopril	239	68
Gabapentin	Gabapentin	229	48
Levothyroxine Sodium	Levothyroxine Sodium	216	57
Amlodipine Besylate	Amlodipine Besylate	197	61
Pantoprazole Sodium	Pantoprazole Sodium	165	57
Metformin Hcl	Metformin Hcl	133	42
Furosemide	Furosemide	129	39
Tamsulosin Hcl	Tamsulosin Hcl	119	34
Methylprednisolone	Methylprednisolone	116	90
Meloxicam	Meloxicam	113	32
Zolpidem Tartrate	Zolpidem Tartrate	106	14
Losartan Potassium	Losartan Potassium	101	31
Hydrochlorothiazide	Hydrochlorothiazide	96	25
Glipizide	Glipizide	85	23
Allopurinol	Allopurinol	81	22
Baclofen	Baclofen	79	45
Tramadol Hcl	Tramadol Hcl	76	28
Pravastatin Sodium	Pravastatin Sodium	75	19
Simvastatin	Simvastatin	75	20
Omeprazole	Omeprazole	70	21
Fenofibrate	Fenofibrate	68	13
Albuterol Sulfate Hfa	Albuterol Sulfate	65	37
Ezetimibe	Ezetimibe	63	15
Rosuvastatin Calcium	Rosuvastatin Calcium	60	17
Ciprofloxacin Hcl	Ciprofloxacin Hcl	59	43
Metoprolol Tartrate	Metoprolol Tartrate	59	16
Azithromycin	Azithromycin	58	45
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	57	48
Benazepril Hcl	Benazepril Hcl	56	16
Clopidogrel	Clopidogrel Bisulfate	55	15
Potassium Chloride	Potassium Chloride	53	15
Ozempic	Semaglutide	49	suppressed
Tizanidine Hcl	Tizanidine Hcl	48	18
Citalopram Hbr	Citalopram Hydrobromide	47	13
Doxycycline Hyclate	Doxycycline Hyclate	43	35
Lorazepam	Lorazepam	43	suppressed
Ropinirole Hcl	Ropinirole Hcl	43	11
Cephalexin	Cephalexin	42	34
Sertraline Hcl	Sertraline Hcl	42	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	40	suppressed
Ventolin Hfa	Albuterol Sulfate	40	18
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	39	suppressed
Montelukast Sodium	Montelukast Sodium	39	15
Clonidine Hcl	Clonidine Hcl	38	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	37	11
Trazodone Hcl	Trazodone Hcl	36	suppressed
Atenolol	Atenolol	35	suppressed
Carvedilol	Carvedilol	34	11
Pregabalin	Pregabalin	34	suppressed
Metoprolol Succinate	Metoprolol Succinate	33	suppressed
Diazepam	Diazepam	31	suppressed
Jardiance	Empagliflozin	31	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	30	suppressed
Eliquis	Apixaban	30	suppressed
Meclizine Hcl	Meclizine Hcl	30	suppressed
Prednisone	Prednisone	30	20
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	29	suppressed
Finasteride	Finasteride	29	suppressed
Mounjaro	Tirzepatide	29	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	28	suppressed
Bupropion Xl	Bupropion Hcl	28	suppressed
Linzess	Linaclotide	28	suppressed
Propranolol Hcl	Propranolol Hcl	27	suppressed
Lovastatin	Lovastatin	26	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	26	suppressed
Alendronate Sodium	Alendronate Sodium	25	suppressed
Breo Ellipta	Fluticasone/Vilanterol	25	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	25	suppressed
Buspirone Hcl	Buspirone Hcl	24	suppressed
Januvia	Sitagliptin Phosphate	24	suppressed
Symbicort	Budesonide/Formoterol Fumarate	24	suppressed
Paroxetine Hcl	Paroxetine Hcl	23	suppressed
Spironolactone	Spironolactone	23	suppressed
Famotidine	Famotidine	22	suppressed
Synthroid	Levothyroxine Sodium	22	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	22	17
Clonazepam	Clonazepam	21	suppressed
Topiramate	Topiramate	21	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	20	suppressed
Glipizide Er	Glipizide	20	suppressed
Methocarbamol	Methocarbamol	20	suppressed
Mupirocin	Mupirocin	20	17
Clindamycin Hcl	Clindamycin Hcl	19	17
Fluoxetine Hcl	Fluoxetine Hcl	19	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	18	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	17	suppressed
Fluconazole	Fluconazole	17	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	16	11
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Amoxicillin	Amoxicillin	15	14
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Gemfibrozil	Gemfibrozil	15	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	15	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	15	suppressed
Atomoxetine Hcl	Atomoxetine Hcl	14	suppressed
Celecoxib	Celecoxib	14	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	14	suppressed
Farxiga	Dapagliflozin Propanediol	14	suppressed
Metronidazole	Metronidazole	14	13
Escitalopram Oxalate	Escitalopram Oxalate	13	suppressed
Propranolol Hcl Er	Propranolol Hcl	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	12	suppressed
Duloxetine Hcl	Duloxetine Hcl	12	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	12	suppressed
Mesalamine Er	Mesalamine	12	suppressed
Metformin Hcl Er	Metformin Hcl	12	suppressed
Nabumetone	Nabumetone	12	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	12	suppressed
Spiriva Respimat	Tiotropium Bromide	12	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	11	suppressed
Irbesartan	Irbesartan	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error